Get the Stockscreener App
6.6486
3.22%
-0.1914
Mind Medicine Inc stock is traded at $6.6486, with a volume of 458.28K.
It is down -3.22% in the last 24 hours and down -18.97% over the past month.
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
See More
Previous Close:
$6.84
Open:
$6.6
24h Volume:
458.28K
Relative Volume:
0.40
Market Cap:
$476.11M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-3.341
EPS:
-1.99
Net Cash Flow:
$-64.37M
1W Performance:
-6.50%
1M Performance:
-18.97%
6M Performance:
-8.18%
1Y Performance:
+80.87%
1-Day Range:
$6.40
$6.67
1-Week Range:
$6.40
$7.8699
52-Week Range:
$3.49
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.65 | 476.11M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.74 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.95 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.19 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.28 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.54 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
(MNMD) Investment Analysis - Stock Traders Daily
Mind Medicine's chief medical officer sells shares worth $49,357 - Investing.com India
Mind Medicine's chief medical officer sells shares worth $49,357 By Investing.com - Investing.com Australia
Mind Medicine CEO Robert Barrow sells shares worth $141,957 By Investing.com - Investing.com Nigeria
Mind Medicine's chief legal officer sells $33,576 in stock - Investing.com India
Mind Medicine CEO Robert Barrow sells shares worth $141,957 - Investing.com India
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Sells $49,357.49 in Stock - MarketBeat
Carrie Liao Sells 2,273 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock - MarketBeat
Mind medicine's chief accounting officer sells shares for $16,888 By Investing.com - Investing.com Canada
Mind Medicine’s chief medical officer sells shares worth $49,357 By Investing.com - Investing.com Nigeria
Mind Medicine's chief legal officer sells $33,576 in stock By Investing.com - Investing.com South Africa
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 8.5%Here's Why - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap DownHere's Why - MarketBeat
MindMed Stock Skyrockets 94% Year to Date: What's Driving It? - MSN
MindMed Stock Skyrockets 94% Year To Date: What's Driving It? - Barchart
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Chardan Capital Initiates Coverage of Mind Medicine (MNMD) with Buy Recommendation - MSN
Mind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by Chardan Capital - MarketBeat
Wellington Management Group LLP Purchases 109,152 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
MindMed joins Nasdaq Biotechnology Index - Investing.com
MindMed to Be Added to the Nasdaq Biotechnology Index - Business Wire
MindMed Joins Nasdaq Biotech Index After Landmark Year of $250M Funding and Clinical Advances - StockTitan
Objective long/short (MNMD) Report - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 4.9% HigherStill a Buy? - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Receives "Outperform" Rating from Oppenheimer - MarketBeat
MindMed doses first subject in trial of tablets for generalised anxiety disorder - Yahoo Finance
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - newsbreak.com
Brokerages Set Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Price Target at $27.71 - MarketBeat
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment By Investing.com - Investing.com South Africa
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment - Investing.com India
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress - Business Wire
Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily
MindMed awarded Innovation Passport for MM120 - The Pharma Letter
Insider Buying: David Gryska Acquires Additional Shares of Mind Medicine Inc (MNMD) - GuruFocus.com
Mind Medicine director David Gryska acquires $17,925 in shares - Investing.com
Mind Medicine director David Gryska acquires $17,925 in shares By Investing.com - Investing.com Nigeria
MindMed gains UK Innovation Passport for GAD treatment - Investing.com
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) - Business Wire
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy - citybiz
MindMed appoints new VP of R&D Strategy - Investing.com
MindMed appoints new VP of R&D Strategy By Investing.com - Investing.com UK
MindMed Announces New Employee Inducement Grants - Business Wire
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3%Time to Sell? - MarketBeat
Ally Bridge Group NY LLC Decreases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine (NEOE:MMED) Change In Inventory : C$0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com
Roth Capital Issues Pessimistic Estimate for MNMD Earnings - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.38 Average Price Target from Brokerages - MarketBeat
Generalized Anxiety Disorder Market to Reach New Heights - openPR
MindMed recruits regulatory expert ahead of Phase III trials - The Pharma Letter
Vera hires Jason Carter as chief legal officer - BioCentury
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mind Medicine Inc Stock (MNMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Liao Carrie | Chief Accounting Officer |
Dec 26 '24 |
Sale |
7.43 |
2,273 |
16,888 |
97,270 |
| Karlin Dan | Chief Medical Officer |
Dec 26 '24 |
Sale |
7.43 |
6,643 |
49,357 |
338,013 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '24 |
Sale |
7.43 |
4,519 |
33,576 |
173,197 |
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):